Protagonist Therapeutics Price to Sales Ratio 2015-2022 | PTGX
Historical PS ratio values for Protagonist Therapeutics (PTGX) over the last 10 years. The current P/S ratio for Protagonist Therapeutics as of July 01, 2022 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Protagonist Therapeutics P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2022-07-01 |
7.86 |
|
8.03 |
| 2022-03-31 |
23.68 |
$0.98 |
24.20 |
| 2021-12-31 |
34.20 |
$0.59 |
57.89 |
| 2021-09-30 |
17.72 |
$0.57 |
31.14 |
| 2021-06-30 |
44.88 |
$0.71 |
63.62 |
| 2021-03-31 |
25.90 |
$0.84 |
30.67 |
| 2020-12-31 |
20.16 |
$0.84 |
24.11 |
| 2020-09-30 |
19.55 |
$0.78 |
25.16 |
| 2020-06-30 |
17.66 |
$0.58 |
30.46 |
| 2020-03-31 |
7.06 |
$0.06 |
121.25 |
| 2019-12-31 |
7.05 |
$-0.01 |
0.00 |
| 2019-09-30 |
12.01 |
$-0.01 |
0.00 |
| 2019-06-30 |
12.11 |
$0.10 |
116.05 |
| 2019-03-31 |
12.57 |
$0.99 |
12.74 |
| 2018-12-31 |
6.73 |
$1.43 |
4.70 |
| 2018-09-30 |
10.29 |
$1.97 |
5.23 |
| 2018-06-30 |
6.72 |
$2.22 |
3.03 |
| 2018-03-31 |
8.59 |
$1.67 |
5.15 |
| 2017-12-31 |
20.80 |
$1.16 |
17.98 |
| 2017-09-30 |
17.67 |
$0.52 |
34.03 |
| 2017-06-30 |
11.31 |
0 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.382B |
$0.027B |
|
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
|
